CRISPR Therapeutics AG (CRSP) ended the recent trading session at $67.74, demonstrating a -6.98% change from the preceding day's closing price. This change lagged the S&P 500's 0.01% gain on the day.

Today, Benzinga's options scanner spotted 14 options trades for CRISPR Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 28% bullish and 42% bearish.

The S&P 500 stock market index has delivered steady returns since it was established in 1957, thanks to its diversified ...

Clinical evidence from studies on atrial fibrillation (AF) and total knee arthroplasty (TKA) indicates that FXI is an appealing target that may upend the $15 billion thromboembolism market, which is ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 23, ...

The Vanguard Total Stock Market Index Fund ETF is a classic pick for savvy long-term investors. That's because the ETF tracks ...

The University of Chicago and Morningstar, Inc. have reached an agreement for Morningstar to acquire the UChicago-affiliated Center for Research in Security Prices (CRSP), a leading source of ...

As part of the transaction, Morningstar will acquire the CRSP Market Indexes, which are the benchmarks for more than $3 trillion in US equities across market capitalizations, investment styles, and ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available this week, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Nvidia built a wide moat around its GPU business. The AI infrastructure market is expected to continue to surge over the next five years. The company is well positioned to continue to capture a big ...

Viking Therapeutics' shares tanked recently after its oral drug, VK2735, spooked investors with a high discontinuation rate. However, it achieved weight loss results similar to Eli Lilly's drug.

CRISPR Therapeutics (NASDAQ:CRSP) traded higher in the premarket on Thursday after J.P. Morgan initiated its coverage with an Overweight recommendation, noting how the company stands out in the gene ...